On a quit-support forum run for people trying to get off nicotine, one person described how it went. They picked up pouches because they wanted to focus. For about a month it was heavy, every day. Then came the flat, tired, disconnected feeling, and a restlessness they couldn’t sit in. They stopped. Late one night they put one back in. Nobody on that thread was confused about the health risks. They were describing something different: a hook that had found a way in through the part of the day where they were trying to do better.
That is the story the FDA’s June order does not tell, so we will.
Zyn is safer than a cigarette and still a hook; the FDA said the first half out loud and left the second off the label.
On June 30, the FDA issued modified-risk orders to Swedish Match USA for 20 Zyn pouch products: ten flavors, each in 3 mg and 6 mg. The company may now say that “using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke,” and then emphysema and chronic bronchitis. The agency found the claim scientifically accurate, found that consumers understand it, and concluded marketing it would benefit the population as a whole. Bret Koplow, the acting director of the Center for Tobacco Products, said the point is giving adult users “clear, science-based information about the relative harms of tobacco products.” The FDA also wrote, in the same release, that “there is no safe tobacco product,” and that quitting everything is the best outcome for adults who smoke.
What the claim says, in plain words
It says: if you smoke cigarettes and you switch completely to this pouch, your odds of those diseases go down. It does not say the pouch is safe. It does not say the pouch helps you stop. Healio’s summary of the order is explicit that these are not approved as cessation aids, and that the case leans heavily on Swedish snus data, not long-term follow-up of Zyn users, which is why the company must run postmarket studies of how people actually use the product and understand the message. The orders last five years and can be pulled if marketing stops serving public health, with a significant rise in youth uptake named as the trigger.
Two gates matter before anyone treats this as practice-changing. First, a marketing authorization is not a treatment authorization: nothing in the order makes a pouch a prescribed quit aid, adds it to a formulary, or changes what a payer covers. Second, the risk-reduction logic applies to adults who would otherwise keep smoking. For a person who has never used nicotine, the correct comparison is not a cigarette. It is nothing.
The people the label wasn’t written for are already holding the can
The FDA’s 2025 National Youth Tobacco Survey found 1.7 percent of middle and high school students currently use nicotine pouches, behind e-cigarettes at 5.2 percent and ahead of cigarettes at 1.4 percent. Overall youth tobacco use fell. Pouches did not. Stanton Glantz, writing in a commentary on the survey, notes pouch use doubled from 0.8 percent in 2021 to 1.7 percent in 2025. A Tobacco Insider summary of the same data reports that 61.4 percent of current youth pouch users name Zyn as their usual brand. Glantz is a long-time critic of the industry, and the pouch figures should be read as a share of survey respondents, not a verdict on any single teenager. They also describe the same market the new label is about to advertise into.
Here is the psychology the label has no room for. Nicotine is a drug that works fast and wears off fast, so the brain learns to expect the next dose before the last one has finished fading. A pouch is easy to hide, easy to repeat, and carries no smell, no cough, no smoke break. Those are the exact things that, for a smoker, might make quitting feel like an event. Take them away and the dependence gets quiet. People describe it the way the forum poster did: not a craving that screams, but a low restlessness that sends a hand to a pocket. If you have ever stopped something and felt the day tilt without it, you know that the hard part is rarely the first hour.
Those are the exact things that, for a smoker, might make quitting feel like an event.
We have been told “lower risk” before, and the hook did not get the memo
In 2006, federal judge Gladys Kessler found that the major cigarette companies had deceptively marketed “light” and “low tar” cigarettes as less harmful, and barred descriptors like “light,” “mild,” and “ultra-light.” Smokers had switched in good faith for decades, trusting the word on the pack. The word on the pack changed how people felt about the cigarette, not what the cigarette did. The lesson was not that lower-risk products are always a lie. It was that a claim about disease risk can be literally true and still work as a reason not to quit. The Zyn order is built differently: it is narrower, evidence-reviewed, and revocable. Whether it plays out differently is a postmarket question nobody can answer in October.
What to do with it this week
If you work in a clinic or a program, change the question. Ask “cigarettes, vapes, pouches, or a mix?” at every tobacco screen, and ask it of the people under 25, who may not count a pouch as tobacco at all. If someone switched to pouches to stop smoking, ask whether they are still smoking. If the answer is “both,” the label’s promise has not reached them. Then offer what is actually approved for quitting, because the order did not change that list. The national quitline, 1-800-QUIT-NOW, is free to everyone and does not require a diagnosis. Overseas, regulators are tightening pouch rules: Britain’s Tobacco and Vapes Act cleared Parliament in April with pouches inside its definition of a nicotine product, which tells you where the argument is headed.
If you’re the one with the can in your pocket and you have already tried to put it down: restlessness is withdrawal, not failure, and a slip is information, not a verdict. Call the quitline the night you slip, not the morning after.
The FDA gave smokers a true sentence. The sentence a person trying to stop actually needs, the one with a phone number in it, still has to come from us.
Sources Cited
- 01.AFDA Authorizes 20 ZYN Nicotine Pouches to Be Marketed with Specific Modified Risk ClaimFDA Center for Tobacco Products
- 02.ANational Youth Tobacco Survey: FDA publishes peer-reviewed journal article, releases 2025 findingsFDA Center for Tobacco Products
- 03.B
- 04.B
- 05.CUSA: Youth Nicotine UseTobacco Insider
- 06.C
- 07.C
Filed Under
psychologypolicytreatment
Keep up with the reporting.
One email each morning with the stories that put days like this in context.